These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 8156530)

  • 1. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ
    Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
    Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
    J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
    Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
    Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.
    Fukumoto S; Matsumoto T; Takebe K; Onaya T; Eto S; Nawata H; Ogata E
    J Clin Endocrinol Metab; 1994 Jul; 79(1):165-70. PubMed ID: 8027221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
    Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
    Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
    J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y; Tomita A; Hasegawa H; Ariyoshi Y; Niinomi M; Yamamoto M; Takano T; Sakiyama N
    Endocr J; 1994 Dec; 41(6):655-61. PubMed ID: 7704089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma PTH and PTH-rP levels and clodronate therapy in cancer patients with hypercalcemia.
    Su RJ; Chang CC; Tsai KS
    J Formos Med Assoc; 1993 Nov; 92(11):977-82. PubMed ID: 7910069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
    Blind E; Raue F; Meinel T; Wüster C; Ziegler R
    Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercalcemia in patients with oral squamous cell carcinoma.
    Iwase M; Kurachi Y; Kakuta S; Sakamaki H; Nakamura-Mitsuhashi M; Nagumo M
    Clin Oral Investig; 2001 Sep; 5(3):194-8. PubMed ID: 11642565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of the parathyrin-related protein (PTH-RP) in the diagnosis of cancer-associated hypercalcemia].
    Sagarra E; Villabona C; Bonnin R; Moliner R; Merino FJ; Sahún M; Soler J
    Med Clin (Barc); 1995 Oct; 105(12):450-4. PubMed ID: 7490935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
    Body JJ; Dumon JC; Thirion M; Cleeren A
    J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy.
    Gallacher SJ; Fraser WD; Logue FC; Dryburgh FJ; Cowan RA; Boyle IT; Ralston SH
    Calcif Tissue Int; 1992 Dec; 51(6):419-23. PubMed ID: 1333351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
    Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
    Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.